Notable Victories Detail Banner
All Notable Victories

Quinn Emanuel Secures Favorable Ruling In Dispute Regarding Foundational CRISPR-Cas9 Patents

March 2022

Quinn Emanuel has secured a pivotal patent ruling for client The Broad Institute, Inc. (“Broad”) in a proceeding involving The Regents of the University of California, University of Vienna, and Emmanuelle Charpentier (“CVC”).  On Monday, February 28, 2022, a three-judge panel of the Patent Trial and Appeal Board (“PTAB”) issued an opinion and judgment confirming Broad’s entitlement to foundational patents directed to the use of CRISPR-Cas9 in eukaryotic cells (including humans, other mammals, and plants).

CRISPR-Cas9 is a revolutionary technology that provides the ability to precisely edit the genome of living cells, and holds enormous potential to accelerate life science research, improve biotechnology, and diagnose and treat human disease.

Broad was represented by a Quinn Emanuel team including Ray Nimrod, who served as lead counsel, Matthew D. Robson, and Zach Summers, along with co-counsel.  


The ruling was covered widely in the press, including in the following: